Cannabis and Endometriosis: When Is an Adverse Effect Not Adverse?

other OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-08

This study found that while 32% of endometriosis patients using cannabis for symptom management reported side effects, some of these may have clinical utility requiring nuanced interpretation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text

This paper reports on a subset of an international survey (n = 889) of people with endometriosis examining self-reported effectiveness, safety, and de-prescribing trends related to cannabis use for pain and associated symptoms. The authors found that 32% of respondents reported side-effects linked to cannabis, with the pattern described as similar to previously published literature, while noting that some adverse effects may have clinical utility and warrant more nuanced interpretation. The main caveat is that the evidence is based on self-reported survey data rather than objective clinical measures, and the paper does not detail specific adverse-effect mechanisms. This paper is centrally about endometriosis — it analyzes cannabis-associated side effects and their interpretation within an endometriosis population.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

There is growing evidence that people with endometriosis are utilising cannabis, whether legally or illicitly procured, for management of pain and associated symptoms. As such, concerns over cannabis use as a medicine are foremost in clinicians' minds, particularly potential adverse effects. This study, a sub-set of a larger (n = 889) international survey investigating the self-reported effectiveness, safety and pharmaceutical de-prescribing trends of cannabis use in the endometriosis population, showed that 32% experienced side-effects associated with cannabis use, similar to published literature. However, some of these reported adverse effects have potential clinical utility and may require a more nuanced interpretation.
Full text 2,236 characters · extracted from oa-doi-fallback · click to expand
Cannabis and Endometriosis: When Is an Adverse Effect Not Adverse? Funding: The authors received no specific funding for this work. ABSTRACT There is growing evidence that people with endometriosis are utilising cannabis, whether legally or illicitly procured, for management of pain and associated symptoms. As such, concerns over cannabis use as a medicine are foremost in clinicians' minds, particularly potential adverse effects. This study, a sub-set of a larger (n = 889) international survey investigating the self-reported effectiveness, safety and pharmaceutical de-prescribing trends of cannabis use in the endometriosis population, showed that 32% experienced side-effects associated with cannabis use, similar to published literature. However, some of these reported adverse effects have potential clinical utility and may require a more nuanced interpretation. Conflicts of Interest As a medical research institute, NICM Health Research Institute receives research grants and donations from foundations, universities, government agencies, individuals and industry. Sponsors and donors also provide untied funding for work to advance the vision and mission of the Institute. Justin Sinclair is the recipient of a Western Sydney University Postgraduate Research Scholarship, and is a current member of the scientific advisory board of United in Compassion (pro bono) and a board member of the Australian Medicinal Cannabis Association (pro bono). Justin Sinclair also sits on the steering committee for Cannabis Clinicians Australia (pro bono) and is employed by Australian Natural Therapeutics Group. Orit Holtzman is the current vice-president of the Australian and New Zealand College of Cannabinoid Practitioners (ANZCCP). Mike Armour is a member of the Endometriosis Australia Clinical Advisory Committee, has done consulting work for Evolv Therapeutics and Hazel outside the submitted work and undertakes clinical trials on medicinal cannabis for Endometriosis funded by the Victorian Government and philanthropic donors. The other authors declare no conflicts of interest. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Medical Marijuana Medical Marijuana Medical Marijuana

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
pubmed
last seen: 2026-06-04T00:30:52.445309+00:00
unpaywall
last seen: 2026-05-11T08:34:28.763810+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine